Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.
David Qixiang Chen, José Adalberto Inzunza Domínguez, Juan Manuel Valle Uzeta, Abhiram P Pushparaj, Jonathan E Dickinson
Frontiers in immunology January 1, 2025 DOI: 10.3389/fimmu.2025.1535782 via PubMed
Summary
AI-generated from the abstractIbogaine treatment in two multiple sclerosis patients led to substantial lesion shrinkage and decreased Apparent Diffusion Coefficient values, suggesting remyelination and reduced inflammation. Both patients showed cortical and subcortical alterations, especially in regions linked to pain and emotional processing. These findings indicate ibogaine may promote neuroplasticity and modulate neurocircuitry involved in MS pathology.
Study at a glance
| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 2 |
| Population | Multiple sclerosis patients |
| Intervention | Ibogaine |
| Topics | Ibogaine |
| Keywords | Multiple sclerosis Neuroimaging Neuroregeneration Psychedelic medicine |
| Citations | 3 |
| Key finding | Ibogaine treatment was associated with lesion shrinkage and neuroimaging changes suggestive of remyelination and reduced inflammation in two MS patients. |
Abstract
Multiple sclerosis (MS) is a debilitating neurodegenerative disease characterized by demyelination and neuronal loss. Traditional therapies often fail to halt disease progression or reverse neurological deficits. Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. Patient A demonstrated substantial lesion shrinkage and decreased Apparent Diffusion Coefficient (ADC) values, suggesting remyelination and reduced inflammation. Both patients exhibited cortical and subcortical alterations, particularly in regions associated with pain and emotional processing. These findings suggest that ibogaine may promote neuroplasticity and modulate neurocircuitry involved in MS pathology.